187 related articles for article (PubMed ID: 29110878)
1. Tumour size, volume, and marker expression during radiation therapy can predict survival of cervical cancer patients: a multi-institutional retrospective analysis of KROG 16-01.
Lee JH; Lee SW; Kim JR; Kim YS; Yoon MS; Jeong S; Kim JH; Lee JY; Eom KY; Jeong BK; Lee SH
Gynecol Oncol; 2017 Dec; 147(3):577-584. PubMed ID: 29110878
[TBL] [Abstract][Full Text] [Related]
2. The Predictive Value of Tumor Size, Volume, and Markers During Radiation Therapy in Patients With Cervical Cancer.
Lee KC; Kim HJ; Sung K; Choi YE; Lee SH; Lim S; Lee KB; Shin JW; Park CY; Kim YS; Sym SJ; Shim YS; Choi SJ
Int J Gynecol Cancer; 2017 Jan; 27(1):123-130. PubMed ID: 27668394
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of tumor measurement parameters and SCC-Ag changes in patients with locally-advanced cervical cancer.
Chen W; Xiu S; Xie X; Guo H; Xu Y; Bai P; Xia X
Radiat Oncol; 2022 Jan; 17(1):6. PubMed ID: 35012582
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of post-radiation serum squamous cell carcinoma antigen and primary tumor regression for cervical squamous cell carcinoma.
Wan Q; Yan W; Liu Y; Lin Y; Lu Z
Cancer Biomark; 2020; 29(3):327-335. PubMed ID: 32716344
[TBL] [Abstract][Full Text] [Related]
5. Magnetic resonance imaging during definitive chemoradiotherapy can predict tumor recurrence and patient survival in locally advanced cervical cancer: A multi-institutional retrospective analysis of KROG 16-01.
Lee SW; Lee SH; Kim J; Kim YS; Yoon MS; Jeong S; Kim JH; Lee J; Eom KY; Jeong BK; Sung SY; Lee SJ; Lee JH
Gynecol Oncol; 2017 Nov; 147(2):334-339. PubMed ID: 28935271
[TBL] [Abstract][Full Text] [Related]
6. The Prognostic Value of Tumor Size, Volume and Tumor Volume Reduction Rate During Concurrent Chemoradiotherapy in Patients With Cervical Cancer.
Sun C; Wang S; Ye W; Wang R; Tan M; Zhang H; Zhou J; Li M; Wei L; Xu P; Zhu G; Lang J; Lu S
Front Oncol; 2022; 12():934110. PubMed ID: 35912169
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of pre-treatment circulating monocyte count in patients with cervical cancer: comparison with SCC-Ag level.
Lee YY; Choi CH; Sung CO; Do IG; Huh S; Song T; Kim MK; Kim HJ; Kim TJ; Lee JW; Kim BG; Bae DS
Gynecol Oncol; 2012 Jan; 124(1):92-7. PubMed ID: 22014631
[TBL] [Abstract][Full Text] [Related]
8. Serum squamous cell carcinoma antigen level and magnetic resonance imaging for the prognosis of locally advanced cervical cancer.
Gu LN; Yu JW; Jiang L; Liu TB; Xu Y
Eur Rev Med Pharmacol Sci; 2024 Jan; 28(2):668-678. PubMed ID: 38305609
[TBL] [Abstract][Full Text] [Related]
9. Pretreatment serum squamous cell carcinoma antigen: a newly identified prognostic factor in early-stage cervical carcinoma.
Duk JM; Groenier KH; de Bruijn HW; Hollema H; ten Hoor KA; van der Zee AG; Aalders JG
J Clin Oncol; 1996 Jan; 14(1):111-8. PubMed ID: 8558185
[TBL] [Abstract][Full Text] [Related]
10. Comparison of clinical outcomes of adenocarcinoma and adenosquamous carcinoma in uterine cervical cancer patients receiving surgical resection followed by radiotherapy: a multicenter retrospective study (KROG 13-10).
Noh JM; Park W; Kim YS; Kim JY; Kim HJ; Kim J; Kim JH; Yoon MS; Choi JH; Yoon WS; Kim JY; Huh SJ
Gynecol Oncol; 2014 Mar; 132(3):618-23. PubMed ID: 24486605
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of pretreatment carcinoembryonic antigen after definitive radiotherapy with or without concurrent chemotherapy for squamous cell carcinoma of the uterine cervix.
Huang EY; Hsu HC; Sun LM; Chanchien CC; Lin H; Chen HC; Tseng CW; Ou YC; Chang HY; Fang FM; Huang YJ; Wang CY; Lu HM; Tsai CC; Ma YY; Fu HC; Wang YM; Wang CJ
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1105-13. PubMed ID: 20932670
[TBL] [Abstract][Full Text] [Related]
12. Elevated circulating tumor cells and squamous cell carcinoma antigen levels predict poor survival for patients with locally advanced cervical cancer treated with radiotherapy.
Wen YF; Cheng TT; Chen XL; Huang WJ; Peng HH; Zhou TC; Lin XD; Zeng LS
PLoS One; 2018; 13(10):e0204334. PubMed ID: 30303986
[TBL] [Abstract][Full Text] [Related]
13. Pretreatment risk factors for parametrial involvement in FIGO stage IB1 cervical cancer.
Yamazaki H; Todo Y; Okamoto K; Yamashiro K; Kato H
J Gynecol Oncol; 2015 Oct; 26(4):255-61. PubMed ID: 26197769
[TBL] [Abstract][Full Text] [Related]
14. The predictive value of serum squamous cell carcinoma antigen in patients with cervical cancer who receive neoadjuvant chemotherapy followed by radical surgery: a single-institute study.
Li X; Zhou J; Huang K; Tang F; Zhou H; Wang S; Jia Y; Sun H; Ma D; Li S
PLoS One; 2015; 10(4):e0122361. PubMed ID: 25860888
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of eukaryotic initiation factor 5A2 (EIF5A2) is associated with cancer progression and poor prognosis in patients with early-stage cervical cancer.
Yang SS; Gao Y; Wang DY; Xia BR; Liu YD; Qin Y; Ning XM; Li GY; Hao LX; Xiao M; Zhang YY
Histopathology; 2016 Aug; 69(2):276-87. PubMed ID: 26799253
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of preoperative intratumoral FDG uptake heterogeneity in early stage uterine cervical cancer.
Chung HH; Kang SY; Ha S; Kim JW; Park NH; Song YS; Cheon GJ
J Gynecol Oncol; 2016 Mar; 27(2):e15. PubMed ID: 26768781
[TBL] [Abstract][Full Text] [Related]
17. Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen.
Bonfrer JM; Gaarenstroom KN; Korse CM; Van Bunningen BN; Kenemans P
Anticancer Res; 1997; 17(3C):2329-34. PubMed ID: 9245246
[TBL] [Abstract][Full Text] [Related]
18. The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy.
Chen CC; Wang L; Lin JC; Jan JS
J Formos Med Assoc; 2015 Mar; 114(3):231-7. PubMed ID: 25777974
[TBL] [Abstract][Full Text] [Related]
19. Squamous cell carcinoma antigen (SCC-Ag) during follow-up of cervical cancer patients: Role in the early diagnosis of recurrence.
Salvatici M; Achilarre MT; Sandri MT; Boveri S; Vanna Z; Landoni F
Gynecol Oncol; 2016 Jul; 142(1):115-119. PubMed ID: 27117922
[TBL] [Abstract][Full Text] [Related]
20. Prospective multi-institutional study of definitive radiotherapy with high-dose-rate intracavitary brachytherapy in patients with nonbulky (<4-cm) stage I and II uterine cervical cancer (JAROG0401/JROSG04-2).
Toita T; Kato S; Niibe Y; Ohno T; Kazumoto T; Kodaira T; Kataoka M; Shikama N; Kenjo M; Tokumaru S; Yamauchi C; Suzuki O; Sakurai H; Numasaki H; Teshima T; Oguchi M; Kagami Y; Nakano T; Hiraoka M; Mitsuhashi N
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):e49-56. PubMed ID: 21470794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
